Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$52 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$-6 Mln
ROE
-5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
256.1
Industry P/E
--
EV/EBITDA
-6
Div. Yield
0 %
Debt to Equity
1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
99,215,200
CFO
$-25.41 Mln
EBITDA
$-48.07 Mln
Net Profit
$-51.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avalon GloboCare (AVCO)
| -- | 1,081.3 | 602.6 | 410.8 | 24.9 | 8.2 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|
|
Avalon GloboCare (AVCO)
| -26.8 | -42.0 | -29.8 | 9.9 | -10.3 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avalon GloboCare (AVCO)
|
3.8 | 52.2 | 1.2 | -11.9 | -673.5 | -404.5 | -- | 256.1 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies,... executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey. Read more
CEO, Pres & Director
Dr. David K. Jin M.D., Ph.D.
CEO, Pres & Director
Dr. David K. Jin M.D., Ph.D.
Headquarters
Freehold, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Avalon GloboCare Corp (AVCO) is $3.78 (NASDAQ) as of 11-Jan-2023 09:30 EDT. Avalon GloboCare Corp (AVCO) has given a return of 24.9% in the last 3 years.
Since, TTM earnings of Avalon GloboCare Corp (AVCO) is negative, P/E ratio is not available.
The P/B ratio of Avalon GloboCare Corp (AVCO) is 256.07 times as on 11-Jan-2023, a 6399 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Avalon GloboCare Corp (AVCO) are Rs -- and Rs -- as of 03-Apr-2026.
Avalon GloboCare Corp (AVCO) has a market capitalisation of $ 52 Mln as on 11-Jan-2023. As per SEBI classification, it is a company.
Before investing in Avalon GloboCare Corp (AVCO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$3.35
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.